Synthesis and Neuroprotective Action of Xyloketal Derivatives in Parkinson’s Disease Models
作者:Shichang Li、Cunzhou Shen、Wenyuan Guo、Xuefei Zhang、Shixin Liu、Fengyin Liang、Zhongliang Xu、Zhong Pei、Huacan Song、Liqin Qiu、Yongcheng Lin、Jiyan Pang
DOI:10.3390/md11125159
日期:——
Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting people over age 55. Oxidative stress actively participates in the dopaminergic (DA) neuron degeneration of PD. Xyloketals are a series of natural compounds from marine mangrove fungus strain No. 2508 that have been reported to protect against neurotoxicity through their antioxidant properties. However, their protection versus 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity is only modest, and appropriate structural modifications are necessary to discover better candidates for treating PD. In this work, we designed and synthesized 39 novel xyloketal derivatives (1–39) in addition to the previously reported compound, xyloketal B. The neuroprotective activities of all 40 compounds were evaluated in vivo via respiratory burst assays and longevity-extending assays. During the zebrafish respiratory burst assay, compounds 1, 9, 23, 24, 36 and 39 strongly attenuated reactive oxygen species (ROS) generation at 50 μM. In the Caenorhabditis elegans longevity-extending assay, compounds 1, 8, 15, 16 and 36 significantly extended the survival rates (p < 0.005 vs. dimethyl sulfoxide (DMSO)). A total of 15 compounds were tested for the treatment of Parkinson’s disease using the MPP+-induced C. elegans model, and compounds 1 and 8 exhibited the highest activities (p < 0.005 vs. MPP+). In the MPP+-induced C57BL/6 mouse PD model, 40 mg/kg of 1 and 8 protected against MPP+-induced dopaminergic neurodegeneration and increased the number of DA neurons from 53% for the MPP+ group to 78% and 74%, respectively (p < 0.001 vs. MPP+ group). Thus, these derivatives are novel candidates for the treatment of PD.
帕金森病(PD)是影响55岁以上人群的第二常见的神经退行性疾病。氧化应激积极参与PD的多巴胺(DA)神经元退化。木酮糖是一系列从海桑菌株No.2508中分离出来的天然化合物,据报道它们通过其抗氧化特性来抵御神经毒性。然而,它们对1-甲基-4-苯基吡啶(MPP+)-诱导的神经毒性的保护作用仅中度,因此需要适当的结构修饰来发现更好的治疗PD的候选药物。在这项工作中,我们设计并合成了39种新的木酮糖衍生物(1-39),以及先前报道的化合物木酮糖B。通过呼吸爆发测定和寿命延长测定,在体内评价了所有40个化合物的神经保护活性。在斑马鱼呼吸爆发试验中,化合物1、9、23、24、36和39在50 μM下强烈抑制活性氧(ROS)的产生。在秀丽隐杆线虫寿命延长试验中,化合物1、8、15、16和36显著延长了存活率(p<0.005与二甲基亚砜(DMSO)相比)。使用MPP+-诱导的C. elegans模型测试了总共 15 种化合物对帕金森病的治疗作用,化合物 1 和 8 表现出最高的活性(p<0.005 vs. MPP+)。在MPP+-诱导的C57BL/6小鼠PD模型中,40 mg/kg 的1和8能保护MPP+诱导的多巴胺神经元退化,并增加DA神经元的数量,从MPP+组的53%分别增加到78%和74%(p<0.001 vs. MPP+组)。因此,这些衍生物是治疗 PD 的新候选药物。